Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Neurogene (NGNE – Research Report) and keeping the price target at ...

Neurogene (NGNE) announced an update on its ongoing Phase 1/2 open-label clinical trial evaluating NGN-401 gene therapy for the treatment of ...

Neurogene (NGNE) shares plunged 36% Monday after the company issued an update on a Phase 1/2 study of its gene therapy ...

Neurogene has dropped plans to keep studying the high dose of its Rett syndrome gene therapy because of an adverse event that ...

Analysts did not seem very concerned by the treatment-related serious adverse event, noting that NGN-401 was well-tolerated ...

Following this update, the company's stock price dropped more than 30 percent from market close Friday to $23.79 per share Monday morning.

Neurogene is proceeding with a scaled-back study of its proposed NGN-401 gene therapy for the rare genetic neurological disorder Rett syndrome after a serious adverse event left a study participant in ...

Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but ...

In an update posted today, Neurogene said that the "emerging treatment-related serious adverse event (SAE)" was a case of systemic hyperinflammatory syndrome, a rare and life-threatening immune ...

Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.

Neurogene (NGNE) announced positive interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase 1/2 open-label trial designed to evaluate NGN-401 gene therapy ...

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases ...